Merck won the Korea Bioprocessing Excellence Award during Biologics Manufacturing Korea 2020 held on October 21. The event, in its ninth year, was conducted virtually due to Covid-19.
Since 2014, IMAPAC, the organizer of Biologics Manufacturing Korea, has held an annual academic meeting at the end of every February with some 400 experts joining from more than 100 governments, NGOs, related businesses and academic institutions, where outstanding enterprises are named and honored in each category. Major participants include global biopharmaceutical companies, CMOs, academia and regulatory bodies from each country, and its seminar topics span from the development, manufacturing, and quality control of biologics to GMP and CMO business. The award recognizes distinguished companies, experts, and groups in each category.
The Korea Bioprocessing Excellence Award was designed to honor outstanding experts, institutions, and technologies in the field of bioprocessing and cell/gene therapy.
“Merck received the award in the category of ‘Bioprocessing Excellence in Upstream Processing’, which means Merck's technology was recognized in the upstream cell culture process. Merck offers a diverse range of products to pharmaceutical and biotechnology companies that enables customers to develop large- and small-molecule drugs safely, effectively and cost-efficiently. It includes single-use manufacturing, filtration, chromatography and purification, virus reduction, pharma and biopharma raw materials, drug delivery compounds and engineering and validation services.” said Yong Kim, Head of Process Solutions, Life Science in Korea.
Merck established the M Lab™ collaboration center, a simulated real manufacturing environment for customers to explore ideas, learn innovative techniques through experiment, hands-on experience at Songdo in 2016. The second commitment to bio-industry development was made at Songdo again, when Merck Life Science Operation Center opened in 2019 to ensure stable supply of life science products and enable tailored services and support to meet R&D and biopharmaceutical growth in Korea. These are the key to help our customers accelerate the speed to market of treatments and therapeutics.
imMEDIAte ADVANTAGE® (Small Volume Custom Media) Lab in Merck Life Science Operation Center: Merck’s imMEDIAte ADVANTAGE® service for pre-GMP, small scale custom media, feeds, supplements and buffers provides the competitive advantage to complete development work quicker and accelerates molecule to market sooner.
